'Not Going With The Crowd’: Mapping Gene Potential With ProFound Therapeutics

Atlas Of Novel Protein Sequences For Discovering First-In-Class Medicines Innovations

John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.  

Genetics
• Source: Shutterstock

Flagship Pioneering, the self-described venture creation company, initiated ProFound Therapeutics four years ago with $75m funding and an undisclosed cash runaway.

"The scientific opportunity here is really unparalleled

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By 

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By 

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By 

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

More from In Vivo

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By 

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.